Sanofi (SNY) raised its full-year 2026 guidance after reporting stronger-than-expected third-quarter results, supported by robust growth in its pharmaceutical launches portfolio and continued strong demand for blockbuster drug Dupixent. The French drugmaker reported third-
Sanofi (SNY) raised its full-year 2026 guidance after reporting stronger-than-expected third-quarter results, supported by robust growth in its pharmaceutical launches portfolio and continued strong demand for blockbuster drug Dupixent.
The French drugmaker reported third-quarter business earnings of â¬3.55 per share
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
